An interventional study of Dietary Supplement: additional substitution of protein and Neuromuscular electrical stimulation in ICU Acquired Weakness, Muscle Atrophy and Energy Malnutrition Protein, sponsored by Technical University of Munich. Recruiting at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-03.
Sponsored by Technical University of Munich · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Muscular Atrophy with a site in Germany — 7 open to participants now, 8 under way, 1 of them phase 3. Muscular Atrophy · Germany.
Among the 23 studies in Muscular Atrophy with a site in Germany, this one is the 14th largest by planned enrollment of the 21 interventional ones that give a count, is one of 5 that started in 2023, is one of 16 with no phase, and was the 15th registered.
413 studies on the registry are indexed under Muscular Atrophy; 76 are open to participants now.
Browse Muscular Atrophy studies →7 of the 23 studies in Muscular Atrophy with a site in Germany are open now. Recruiting first, the newest first:
University of Erlangen-Nürnberg Medical School · Sites in Germany
Ages 18+
Universitätsklinikum Hamburg-Eppendorf · Sites in Germany
Ages 18+ · Women only
University Hospital of Cologne · Sites in Germany
Ages 18+
Medical University of Vienna · Sites in Germany, Austria, Italy
Ages 18+
University of Erlangen-Nürnberg Medical School · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 51 Muscular Atrophy studies recruiting now, 25 (49%) set no upper age limit and 13 (25%) stop at 75 or younger; 4 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is close to the median of 40 across 327 interventional studies indexed under Muscular Atrophy.
Median enrollment 130 across the 21 interventional studies, 472 across the 2 observational. Of the 12 that completed or were terminated, 2 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 23 have an industry lead sponsor. The 10 most frequent:
Technical University of Munich is the lead sponsor of 323 studies on the registry; 61 are open to participants now.
Technical University of Munich has 1 study filed under Muscular Atrophy — fewer than ten, so there is no comparison to draw.
1 of the studies in Muscular Atrophy with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05919940Technical University of MunichImproved Muscle Metabolism by Combination of Muscle Activation and Protein Substitution ( IMEMPRO ) | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies in Muscular Atrophy with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Intensive Care Unit Acquired Weakness (ICUAW) describes muscle weakness that occurs in around 40% of patients during an intensive care stay. The morbidity and mortality of these patients is significantly increased over a 5-year period. The aim of this study is to investigate the combined effect of early enteral high-protein nutrition and early muscle activation on muscle atrophy in critically ill patients.
The study will include 40 patients (20 intervention, 20 observation) with requirement for enteral nutrition at time of inclusion. In the intervention group the maximum possible level of mobilization is carried out and muscles are activated twice a day using neuromuscular electrical stimulation (NMES). The nutrition plan of the intervention group is based on the applicable guidelines for intensive care medicine with exception of increased protein intake. The control group receives therapy without deviating from the standard according of the DGEM guideline.
The study aims to show that the decrease in muscle mass is significantly less than in the control group (primary hypothesis) via ultrasound of the rectus femoris muscle and in case of given consent muscle biopsy. As secondary hypothesis it is examined whether the combination of early high protein intake and muscle activation improves muscle strength and endurance.
Intensive Care Unit Acquired Weakness (ICUAW) describes the clinically diagnosed manifestation of a neuromuscular organ dysfunction. It develops in approximately 40% of all intensive care unit patients amounting to at least 1.2 million patients annually in Germany. All these patients face a broad range of sequeleae and an increased mortality up to 5 years after ICU discharge. A characteristic pathophysiological phenomenon is an early severe muscle atrophy reaching 10% during the first days after ICU admission.
The current preventative and therapeutic approach for ICUAW is a combination of targeted risk factor management as well as early activation of muscles, i.e. neuromuscular electrical stimulation (NMES) and early mobilization as they have been shown to counteract the muscle atrophy and mediate different outcome benefits such as shorter ICU stay.
Nutrition is a key element of our daily life. Protein intake has been shown to affect lean mass and muscle mass. Research into specific nutritional strategies to treat or prevent ICUAW are scarce and the combination with early muscle activation has not been adequately explored.
The study will include 40 patients (20 intervention, 20 observation) who were admitted to an intensive care unit within the last 48 hours. A basic requirement for inclusion is an indication for enteral (via the gastrointestinal tract) nutrition at time of inclusion. In the intervention group, the ability to mobilize is assessed daily and the maximum possible level of mobilization is carried out and additional muscles are activated twice a day using neuromuscular electrical stimulation (NMES). The nutrition plan of the intervention group is based on the applicable guidelines for intensive care medicine. In this study, protein intake is increased in the interventional group. The control group receives therapy without deviating from the standard according to the SOP and DGEM guideline: "Clinical nutrition in intensive care medicine" 2018.
The study aims to show that the decrease in muscle mass is significantly less than in the control group (primary hypothesis) via ultrasound of the rectus femoris muscle and muscle biopsy. As a second hypothesis it is examined whether the combination of early high protein intake and muscle activation improves muscle strength and endurance compared to the control group.
Further exploratory analyses will investigate changes in the skeletal muscle glycogen content, skeletal muscle histology, skeletal muscle gene expression, skeletal muscle protein level, as well as metabolomic changes in blood and urine.
An additional blood sample will be taken after 90 days as part of a follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
High protein substitution plus NMES and EM
Dietary Supplement: Dietary Supplement: additional substitution of protein · Device: Neuromuscular electrical stimulation · Other: Early Mobilization
Nutrition and mobilization are carried out according to standard of care.
Day one (admission) no nutrition is applied. Protein target is increased as follows: * to a level of 1,2g/kg/d on day 1 after ICU admission * to a level of 1,4g/kg/d on day 2 after ICU admission * to a level of 1,6g/kg/d on day 3 after ICU admission * to a level of 1,8g/kg/d on day 4 after ICU admission * to a level of 2,0g/kg/d from day 5 onwoards Additional protein is given within 2 hours after mobilization respectively: * to 0,125g/kg/d on day 1 after ICU admission * to 0,2g/kg/d on day 2 after ICU admission * to 0,25g/kg/d on day 3 after ICU admission * to 0,3g/kg/d from day 4 after ICU admission onwoards
twice daily 60 minutes till day 28 or ICU discharge
at least 20 minutes a day following the SOMS concept. Duration: till 28 day or ICU discharge
Change in cross sectional area (ΔCSA) of the rectus femoris
Change in muscle mass between study inclusion and study day 14; measured as change of the cross sectional area (ΔCSA) of the rectus femoris muscle via ultrasound.
Time frame: day 1 (study inclusion) and 14 days
change in muscle thickness of the rectus femoris
change in muscle thickness from study inclusion until 90-day follow-up, measured via ultrasound.
Time frame: day 1 (study inclusion) until 90-day Follow-up
change in echogenicity of the rectus femoris
change in echogenicity from study inclusion until 90-day follow-up, measured via ultrasound.
Time frame: day 1 (study inclusion) until 90-day Follow-up
change of the pennation angle of the rectus femoris
change of the pennation angle from study inclusion until 90-day follow-up, measured via ultrasound.
Time frame: day 1 (study inclusion) until 90-day Follow-up
change of the muscle strength, measured by the Medical Research Council score (MRC-score)
change of the muscle strength, measured by the Medical Research Council score (MRC-score) from study inclusion until 90-day follow-up
Time frame: day 1 (study inclusion) until 90-day Follow-up
change of the muscle strength, measured by handgrip dynamometry
change of the muscle strength, measured by handgrip dynamometry from study inclusion until 90-day follow-up
Time frame: day 1 (study inclusion) until 90-day Follow-up
change in muscle endurance
change in muscle endurance, measured by the 6-minute walking test up to 90-day follow-up
Time frame: up to 90 day follow up
change in physical physical function
change in physical physical function, measured by the Short Physical Performance Battery up to 90-day follow-up
Time frame: up to 90-day follow-up
development of quality of life
development of quality of life, measured by the Short Form-36 up to 90-day follow-up
Time frame: up to 90-day follow-up
change in Skeletal muscle mass
change in Skeletal muscle mass, measured with bioelectrical impedance analysis up to 90-day follow-up.
Time frame: day 1 (study inclusion) until 90-day Follow-up
change in extracellular volume
change in extracellular volume, measured by the Body impedance analysis
Time frame: day 1 (study inclusion) until 90-day Follow-up
change in the REE (Resting Energy Expenditure)
change in the REE (Resting Energy Expenditure), measured by indirect calorimetry
Time frame: day 1 (study inclusion) until 90-day Follow-up
urea-to-creatinine ratio
urea-to-creatinine ratio from blood sample
Time frame: day 1 (study inclusion) until 90-day Follow-up
Identify possible predictors of muscle wasting in urine metabolomics at ICU admission
Among the urine metabolomics that will be measured, identify metabolites or combinations of metabolites whose high or low concentration(s) at ICU admission associate(s) with the amount of muscle loss. These metabolites are candidate biomarkers that could be used to identify individuals at risk of large muscle wasting and may give further insights into the mechanisms of muscle wasting.
Time frame: day 1 (study inclusion) until 90-day Follow-up
Identify possible predictors of muscle wasting in the blood metabolome at ICU admission
Among the blood metabolome that will be measured, identify metabolites or combinations of metabolites whose high or low concentration(s) at ICU admission associate(s) with the amount of muscle loss. These metabolites are candidate biomarkers that could be used to identify individuals at risk of large muscle wasting and may give further insights into the mechanisms of muscle wasting.
Time frame: day 1 (study inclusion) until 90-day Follow-up
in-hospital mortality
Mortality during the Hospital stay
Time frame: until 90-day Follow-up
Hospital LOS
Length of stay in the hospital
Time frame: until 90-day Follow-up
ICU-LOS
Length of stay in the ICU
Time frame: until 90-day Follow-up
Hospital mortality
Mortality during Hospital stay
Time frame: until 90-day Follow-up
Duration of Mechanical ventilation
Duration of invasive mechanical ventilator dependency
Time frame: until 90-day Follow-up
ICU mortality
Mortality during ICU stay
Time frame: until 90-day Follow-up
enzyme function in the rectus femoris
Spectrophotometry will be done in muscle samples. All samples will be screened for influence of Intensive Care Unit Acquired Weakness (ICUAW) and correlation with blood metabolome changes.
Time frame: according to biopsy inbetween day 1-7
protein content in the rectus femoris
Western Blot will be done in muscle samples. All samples will be screened for influence of Intensive Care Unit Acquired Weakness (ICUAW) and correlation with blood metabolome changes.
Time frame: according to biopsy inbetween day 1-7
geneexpression in the rectus femoris
qPCR (quantitive polymerase chain reaction) will be done in muscle samples. All samples will be screened for influence of Intensive Care Unit Acquired Weakness (ICUAW) and correlation with blood metabolome changes.
Time frame: according to biopsy inbetween day 1-7
Muscle morphology of the rectus femoris
Light-and Electron-Microscopy will be done in muscle samples. All samples will be screened for influence of Intensive Care Unit Acquired Weakness (ICUAW) and correlation with blood metabolome changes.
Time frame: according to biopsy inbetween day 1-7
Not enrolling at this site.
Not enrolling at this site.
Plan to share: Yes — Deidentified data can be requested on reasonable scientific request and data sharing contract, if necessary.
Supporting information: Study protocol, Informed consent form
Time frame: After publication of scientific manuscript.
Access criteria: Deidentified data can be requested on reasonable scientific request and data sharing contract, if necessary.
No publications or documents are linked to this record.
Started Jun 2023 (actual). Primary completion is estimated for Dec 2026, 42 months after the start.
Of 170 non-industry interventional studies with no phase under Muscular Atrophy, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 38. This study's planned 42 months is above that.
Counting every sponsor, half of 176 studies reached it within 21 months; a quarter within 9 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Technical University of Munich →